A canine gallbladder disease that involves the accumulation of abnormal mucus similar to that seen in human cystic fibrosis (CF) patients is caused by improper expression of the gene associated with CF in humans. The finding could have implications for human CF patients as well as for animal models of CF. A canine gallbladder disease
Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, triple combination therapy makes it possible to address the root causes of the defect underlying the disease. This form of treatment was recently approved for
A canine gallbladder disease that involves the accumulation of abnormal mucus similar to that seen in human cystic fibrosis (CF) patients is caused by improper expression of the gene associated with CF in humans. The finding could have implications for human CF patients as well as for animal models of CF. A canine gallbladder disease
A canine gallbladder disease that involves the accumulation of abnormal mucus similar to that seen in human cystic fibrosis (CF) patients is caused by improper expression of the gene associated with CF in humans. The finding could have implications for human CF patients as well as for animal models of CF. A canine gallbladder disease
Researchers uncovered new information about the role inflammation plays in mitigating liver fibrosis, which is associated with metabolic-associated fatty liver disease (MAFLD), one of the most common diseases in the world affecting up to 40 percent of U.S. adults. Researchers at UCLA Health uncovered new information about the role inflammation plays in mitigating liver fibrosis
Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, triple combination therapy makes it possible to address the root causes of the defect underlying the disease. This form of treatment was recently approved for
A canine gallbladder disease that involves the accumulation of abnormal mucus similar to that seen in human cystic fibrosis (CF) patients is caused by improper expression of the gene associated with CF in humans. The finding could have implications for human CF patients as well as for animal models of CF. A canine gallbladder disease
Researchers uncovered new information about the role inflammation plays in mitigating liver fibrosis, which is associated with metabolic-associated fatty liver disease (MAFLD), one of the most common diseases in the world affecting up to 40 percent of U.S. adults. Researchers at UCLA Health uncovered new information about the role inflammation plays in mitigating liver fibrosis
Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, triple combination therapy makes it possible to address the root causes of the defect underlying the disease. This form of treatment was recently approved for
Cystic fibrosis is one of the most common genetic disorders, causing thick mucus build-up in the lungs and other parts of the body, breathing problems, and infection. Now, researchers have developed a gene-editing approach that efficiently corrects the most common mutation that causes cystic fibrosis, found in 85 percent of patients. With further development, it
Pseudomonas aeruginosa -- an environmental bacteria that can cause devastating multidrug-resistant infections, particularly in people with underlying lung conditions -- evolved rapidly and then spread globally over the last 200 years, probably driven by changes in human behavior, a new study has found. Pseudomonas aeruginosa -- an environmental bacteria that can cause devastating multidrug-resistant infections
, conditions that can result in severe damage to the body's tissues. This groundbreaking method aims to deliver drugs directly to the affected areas, providing more targeted and effective treatment. By utilizing nanoparticles, this approach offers the potential for reduced side effects and improved patient outcomes. The innovative work being done at The University of Texas at El Paso showcases the potential for a new and promising avenue in the treatment of fibrotic diseases
